Trodelvy (sacituzumab govitecan) for the Treatment of Advanced Triple-Negative Breast Cancer
Trodelvy is a Trop-2-directed antibody and topoisomerase inhibitor conjugate. Credit: Alexkich/Shutterstock.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more
